Partnering Interest In Infectious Disease Space Showing Promise Beyond HCV Hotspot
Antiviral agents and vaccines for indications beyond the red-hot hepatitis C indication highlight the infectious diseases track at this year’s Therapeutic Area Partnerships conference.
You may also be interested in...
Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.
Agenus will have sufficient cash to last through 2013 as it focuses on furthering its immunotherapeutics, including HerpV for genital herpes and Prophage Series G vaccines for glioma.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.